In this study, we investigated the prospects of endogenous-ADAR to target inherited variants associated with cancer risk in pediatric syndromes and adults with high-penetrance disease, as well as treating cancer by correcting driver mutations in tumors. This evidence concerns the gene ADAR and cancer.